ATOS vs. IXHL, IVA, OGI, ACRV, TELO, LFCR, ZVRA, TRVI, CDT, and GALT
Should you be buying Atossa Therapeutics stock or one of its competitors? The main competitors of Atossa Therapeutics include Incannex Healthcare (IXHL), Inventiva (IVA), Organigram (OGI), Acrivon Therapeutics (ACRV), Telomir Pharmaceuticals (TELO), Lifecore Biomedical (LFCR), Zevra Therapeutics (ZVRA), Trevi Therapeutics (TRVI), Conduit Pharmaceuticals (CDT), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical preparations" industry.
Atossa Therapeutics (NASDAQ:ATOS) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations.
Atossa Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 251.44%. Given Atossa Therapeutics' higher possible upside, equities analysts clearly believe Atossa Therapeutics is more favorable than Incannex Healthcare.
Atossa Therapeutics received 230 more outperform votes than Incannex Healthcare when rated by MarketBeat users.
12.7% of Atossa Therapeutics shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 7.8% of Atossa Therapeutics shares are held by company insiders. Comparatively, 14.6% of Incannex Healthcare shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Atossa Therapeutics had 21 more articles in the media than Incannex Healthcare. MarketBeat recorded 23 mentions for Atossa Therapeutics and 2 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 1.51 beat Atossa Therapeutics' score of 0.64 indicating that Incannex Healthcare is being referred to more favorably in the news media.
Incannex Healthcare's return on equity of 0.00% beat Atossa Therapeutics' return on equity.
Incannex Healthcare has higher revenue and earnings than Atossa Therapeutics.
Atossa Therapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Incannex Healthcare has a beta of 8.65, suggesting that its stock price is 765% more volatile than the S&P 500.
Summary
Incannex Healthcare beats Atossa Therapeutics on 7 of the 12 factors compared between the two stocks.
Get Atossa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atossa Therapeutics Competitors List
Related Companies and Tools
